Exercise and Nutrition Interventions in Age-related Sarcopenia
- Conditions
- SarcopeniaMuscular Atrophy
- Interventions
- Dietary Supplement: Protein SupplementationOther: Aerobic ExerciseOther: Resistance Exercise
- Registration Number
- NCT02912130
- Lead Sponsor
- Liverpool Hope University
- Brief Summary
This project will investigate the synergistic effects of Aerobic and Resistance type Exercise, in combination with Protein Supplementation, on; Body Composition, Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia.
- Detailed Description
Musculoskeletal ageing is an inevitable process associated with profound morphological and functional changes that will ultimately transition an individual from independent, to dependable living, relying heavily on personal health care for survival. The United Kingdom (UK) population aged over 65 years is expected to rise from 8.8 to 11.3 million by 2025. As life expectancy increases due to advances in medical treatment, an age-related disease termed sarcopenia, has become more prevalent in the elderly. Sarcopenia, described as the loss of musculoskeletal mass, strength and/or physical functioning with age, manifests after the 6th decade and rapidly increases after the 8th decade, resulting in a deterioration of health status and quality of life. To manage the looming health and economic consequences of sarcopenia, suitable therapeutic strategies to manage the condition are warranted. Therefore, this randomised control trial (RCT) will investigate the effects of 16-weeks of exercise and nutritional interventions in inactive senior citizens (60 - 90 years old).
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 160
- Male and Female participants
- 60 - 90 years of age
- Resident in North West, England, UK
- BMI 18.5-30 kg/m
- Can speak and understand English
- Willing to consent and follow the study procedures
- Recent (i.e. past 3 months) or concurrent participation in any clinical trial or dietary and/or exercise intervention program
- Self-reported lactose intolerance
- Uncontrolled diabetes (HbA1C >10)
- Uncontrolled Hypertension (160/100) and uncontrolled hypotension (<100 systolic)
- Treatment with Beta Blockers, Calcium Channel Blockers, Digitalis, Bronchodilator,
- Diuretics, Vasodilators
- Current hormone therapy such as insulin, testosterone or hormone replacement therapy
- History of falls/osteoporosis
- Major psychological/mental illness
- Medical conditions that precluded safe participation in an exercise program
- Other major systemic diseases: Liver and kidney diseases, Advanced gastrointestinal disorders, Cardiovascular Diseases, Advanced chronic obstructive pulmonary disease, Advanced Rheumatoid Arthritis, Cancer
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Nutrition Protein Supplementation Dietary Supplement: Protein Supplementation i.e. 1.2-1.5g/kg/body weight per day Exercise Aerobic Exercise 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Resistance Exercise i.e. 60 minutes per week of progressive resistance training Exercise Resistance Exercise 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Resistance Exercise i.e. 60 minutes per week of progressive resistance training Exercise+Nutrition Aerobic Exercise 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day Exercise+Nutrition Protein Supplementation 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day Exercise+Nutrition Resistance Exercise 1. Aerobic Exercise i.e. 30-60 minutes per week of moderate intensity exercise 2. Dietary Supplement i.e. Protein Supplementation 1.2-1.5g/kg/body weight per day
- Primary Outcome Measures
Name Time Method Body Composition: Lean Muscle/Fat Tissue 1) appendicular lean mass (kg) divided by height (meters-squared) and 2) appendicular lean mass divided by body mass index 16 weeks
- Secondary Outcome Measures
Name Time Method Grip Strength: Hand Grip Dynanometer (kg) 16 weeks Time to complete five chair rises (m/s) 16 Weeks Exercise Tolerance: Six Minute Walk Test (metres) 16 Weeks Biochemical: Insulin-Like Growth Factor 1 (IGF-1) (ng/ml) 16 Weeks Gait speed during timed 4-meter walk (m/s) 16 Weeks Balance assessment: 1) feet side to side, 2) semi-tandem, 3) full tandem, and 4) single leg. Scored as Yes or No. 16 Weeks Isometric Strength - Knee Flexion/Extension: Dynanometer (Nm/Kg) 16 Weeks Biochemical: C-Reactive Protein (CRP) (mg/L) 16 Weeks Arterial Pressure: Pulse Wave Velocity (m/s) 16 Weeks World Health Organization Quality Of Life Assessment (WHOQOL): Each question is scored from 1-5 on a response scale 16 Weeks Muscle Fatigue: Upper & Lower limb: 25% of MVC during 60 seconds using Electromyography (EMG), measured in millivolts (mV) 16 Weeks Energy Balance: Periodic Food Diary (Kcal) 16 Weeks 10-metre Gait analysis during habitual walking speed using Electromyography (EMG) 16 Weeks 10-metre Gait analysis during habitual walking speed using Three-Dimensional Motion Capture - 1) Spatiotemporal, 2) Kinematics 16 Weeks Short-Form Health Survey (SF-12): Each question is scored between 1-6 on a response scale 16 Weeks Activities of Daily Living (ADL): Each response is scored as either: 0 or 1 16 Weeks Mini-Mental State Examination (MMSE): Each correct response is scored as 1 point 16 Weeks Nutritional Status: Mini-Nutritional Assessment (MNA) - Classified as (Low, Moderate, High risk) 16 weeks Biochemical: Glycated Haemoglobin (HBA1c) (%) 16 Weeks
Trial Locations
- Locations (1)
Liverpool Hope University
🇬🇧Liverpool, Merseyside, United Kingdom